



Universiteit
Leiden
The Netherlands

Expanding the chemical space of antibiotics produced by *Paenibacillus* and *Streptomyces*

Machushynets, N.V.

Citation

Machushynets, N. V. (2024, September 5). *Expanding the chemical space of antibiotics produced by Paenibacillus and Streptomyces*. Retrieved from <https://hdl.handle.net/1887/4082475>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4082475>

Note: To cite this publication please use the final published version (if applicable).



Chapter 5

Discovery of actinomycin L, a new member of the actinomycin family of antibiotics

Nataliia V. Machushynets, Somayah S. Elsayed, Chao Du,
Maxime A. Siegler, Mercedes de la Cruz, Olga Genilloud,
Thomas Hankemeier and Gilles P. van Wezel

This chapter was published as:

Machushynets N.V., Elsayed S.S., Du C., Siegler M.A., de la Cruz M., Genilloud O., Hankemeier T., & van Wezel G.P. (2022). Discovery of actinomycin L, a new member of the actinomycin family of antibiotics. *Sci Rep.*, **12**, 2813.

Abstract

Streptomycetes are major producers of bioactive natural products, including the majority of the naturally produced antibiotics. While much of the low-hanging fruit has been discovered, it is predicted that less than 5% of the chemical space of natural products has been mined. Here, we describe the discovery of the novel actinomycins L₁ and L₂ produced by *Streptomyces* sp. MBT27, via application of metabolic analysis and molecular networking. Actinomycins L₁ and L₂ are diastereomers, and the structure of actinomycin L₂ was resolved using NMR and single-crystal X-ray crystallography. Actinomycin L is formed via spirolinkage of anthranilamide to the 4-oxoproline moiety of actinomycin X₂, prior to the condensation of the actinomycin halves. Such a structural feature has not previously been identified in naturally occurring actinomycins. Adding anthranilamide to cultures of the actinomycin X₂ producer *Streptomyces antibioticus*, which has the same biosynthetic gene cluster as *Streptomyces* sp. MBT27, resulted in the production of actinomycin L. This supports a biosynthetic pathway whereby actinomycin L is produced from two distinct metabolic routes, namely those for actinomycin X₂ and for anthranilamide. Actinomycins L₁ and L₂ showed significant antimicrobial activity against Gram-positive bacteria. Our work shows how new molecules can still be identified even in the oldest of natural product families.

Introduction

Considering the emerging crisis of antibiotic resistance that spreads among bacterial pathogens and increasing incidence of cancer, the search for new, efficient and less toxic drugs remains a priority (Wright, 2015, Silver, 2011). Actinobacteria have been the source for the majority of the antibiotics in use today (Barka *et al.*, 2016, Bérdy, 2005). Of the Actinobacteria, members of the genus *Streptomyces* produce over half of all currently characterized antibiotics (Barka *et al.*, 2016). Genome sequencing revealed that Actinobacteria have much more biosynthetic potential to produce bioactive molecules than originally anticipated, with even the model organisms harboring many so-called cryptic or silent biosynthetic gene clusters (BGCs) that specify yet unknown compounds (Bentley *et al.*, 2002, Cruz-Morales *et al.*, 2013, Ikeda *et al.*, 2003). Triggering the expression of silent BGCs by genetic and cultivation-based techniques should facilitate unlocking this yet unexplored chemical diversity, allowing the discovery of novel molecules (Rutledge & Challis, 2015, van Bergeijk *et al.*, 2020). This strategy relies on altering the regulatory networks of the producing organism in response to fluctuating culturing conditions, such as carbon, nitrogen or phosphate concentration (Urem *et al.*, 2016, van der Heul *et al.*, 2018, Sanchez *et al.*, 2010). Manipulation of fermentation conditions of promising producer strains, known as “one strain many compounds” (OSMAC) approach, is effective in enhancing secondary metabolites production (Bode *et al.*, 2002, Romano *et al.*, 2018). Novel secondary metabolites have been discovered via modification of cultivation parameters, including nutrients (Yoon & Nodwell, 2014, Zhu *et al.*, 2014a), and the addition of chemical elicitors (Craney *et al.*, 2012, Rigali *et al.*, 2008).

Metabolic profiling of crude extracts obtained under different growth conditions represents a challenging analytical task since these mixtures are composed of hundreds of natural products. Therefore, metabolomics, particularly those based on mass spectrometry (MS), became more and more valuable and greatly increased the efficiency of such screenings (Demarque *et al.*, 2020). Supervised statistical methods are able to classify a response like a biological activity, and to determine the most discriminant metabolite(s) related to such response (O’Leary *et al.*, 2016). Moreover, simultaneous dereplication of differentially expressed compounds is implemented into the drug-discovery pipelines in order to avoid rediscovery of already known compounds (Gaudencio & Pereira, 2015). MS-based metabolomics provides important information on the distribution of the metabolites that are present in complex mixtures, but the identification of their structures is complicated. For this purpose, the Global Natural Products Social molecular networking (GNPS MN) was developed, applying both molecular networking and automated searches of tandem mass spectrometry (MS/MS) fragmentation spectra against spectral libraries, to identify structural relationships between metabolites (Nguyen *et al.*, 2013, Wang *et al.*, 2016). This greatly

facilitates the annotation and dereplication of known molecules.

Actinomycin is a DNA-targeting antibiotic and anticancer compound discovered in 1940 by Waksman and Woodruff and in fact, the first antibiotic that was isolated from an Actinobacteria (Waksman & Woodruff, 1940). Actinomycins are produced by various *Streptomyces* strains and are composed of a chromophore group and two pentapeptide chains with a variable composition of amino acids (Figure S1) (Katz, 1967). Actinomycins D, X_{0β} and X₂ are usually simultaneously produced and differ from each other by substitutions on the proline residue in their pentapeptide lactone rings, while members of the actinomycin C complex vary in their D-valine residues (Crnovcic *et al.*, 2017). The pentapeptide precursors are biosynthesized by a nonribosomal peptide synthetase (NRPS) assembly line, and actinomycins are formed through oxidative condensation of two 3-hydroxy-4-methylantranilic acid (4-MHA) pentapeptide lactones (PPLs) (Crnovčić *et al.*, 2014).

In this work, we report the discovery of new actinomycin analogs, actinomycin L₁ and L₂, from the extracts of *Streptomyces* sp. MBT27. Multivariate data analysis combined with molecular networking indicated that the antimicrobial activity of the extracts correlated with novel actinomycins L₁ and L₂ and known actinomycins D, X_{0β} and X₂. NMR and single-crystal X-ray crystallography revealed that an anthranilamide moiety was linked through a spiro-center to a proline residue in the structure of actinomycins L₁ and L₂. Such a structural feature has not previously been identified in naturally occurring actinomycins.

Results

The influence of carbon sources on bioactivity and actinomycin production

Streptomyces sp. MBT27 is a gifted natural product producer that was isolated from Qinling mountains in China, with potent antibacterial activity against various MDR (multi-drug resistant) bacteria (Zhu *et al.*, 2014a). We previously showed that the strain, among others produces the novel quinazolinones A and B (Machushynets *et al.*, 2019). To investigate the antibiotic activity of *Streptomyces* sp. MBT27 the strain was fermented in minimal medium (MM) with either of the following carbon sources (percentages in w/v): 1% of both mannitol and glycerol, 1% mannitol, 2% mannitol, 1% glycerol, 2% glycerol, 1% glucose, 2% glucose, 1% fructose, 1% arabinose, or 1% *N*-acetylglucosamine (GlcNAc). Supernatants of *Streptomyces* sp. MBT27 cultures were extracted with ethyl acetate and bioactivity assays were performed against *Bacillus subtilis* 168. Interestingly, the carbon sources had a huge effect on the antimicrobial activity (Figure S2). Particularly strong antimicrobial activity was observed when the culture medium was supplemented with glycerol + mannitol, glucose 1%, glycerol, fructose or GlcNAc; as compared to when mannitol or arabinose were used as the carbon sources.

In order to investigate the metabolic differences due to nutritional supplementation and correlate that to the antimicrobial activity, LC-MS-based metabolomics was performed. Initially, the LC-MS data were explored by unsupervised Principal Component Analysis (PCA). The first two PCs accounted for 37% and 16%, respectively, of the total data variation. PCA analysis failed to show significant metabolic separation in relation to the observed bioactivity (Figure 1A). The supervised Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA) was then applied to discriminate the samples based on their ability to inhibit *B. subtilis* (Figure 1B). The cross-validation metrics of the model ($R^2Y = 0.748$ and $Q^2Y = 0.676$) indicated that the model has good reliability and ability of prediction. A permutation test was performed ($n = 100$) and the resulting R^2Y and Q^2Y values were significantly lower (p values < 0.01 for both), which indicated that there was no overfitting in the model (Figure S3) (Chong *et al.*, 2019). The OPLS-DA loadings S-plot revealed the most discriminative features between active and inactive groups (Figure 1C).




Figure 1. Differential production of metabolites depending on the carbon source.

A. PCA score plot of *Streptomyces* sp. MBT27 metabolites produced in cultures with different carbon sources, namely, 1% arabinose, 1% fructose, 1% GlcNAc, 1% glucose, 2% glucose, 1% glycerol, 2% glycerol, 1% mannitol, 1% mannitol + 1% glycerol and 2% mannitol (%ages in w/v). **B.** OPLS-DA score plot. Triangles and crosses represent samples of active and inactive groups respectively, circular areas represent the 95% confidence region of each group. **C.** OPLS-DA loadings S-plot. Arrows indicate the most discriminative features that positively correlate with the bioactive group.

The mass features that correlated best to the bioactivity were m/z 1387.6706 (8.8 min), m/z 1255.6353 (8.53 min), m/z 1277.6175 (8.52 min), m/z 1271.631 (7.56 min) and m/z 1293.612 (7.56 min) (Figure 1C). Dereplication of those features was performed through comparison of the UV spectra, accurate masses, isotope distribution and fragmentation patterns obtained in MS/MS analysis against the chemistry databases Reaxys, ChemSpider, and the microbial natural products database Antibase (Laatsch, 2012b). This allowed us to annotate the mass features with m/z 1255.6353 and 1277.6175 as the $[M+H]^+$ and $[M+Na]^+$ adduct ions of actinomycin D, respectively, while the mass features with m/z 1271.631 and 1293.612 were annotated as $[M+H]^+$ and $[M+Na]^+$ adduct ions of actinomycin $X_{0\beta}$, respectively (Crnovčić *et al.*, 2014). However, the mass feature with an m/z value of 1387.6706 $[M+H]^+$ could not be matched to any of the previously reported microbial natural products.

Global Natural Product Social (GNPS) molecular networking (Wang *et al.*, 2016) was subsequently employed to detect MS/MS-based structural relatedness among features in an automated manner. The web-based platform generates a molecular network wherein features with related scaffolds cluster together. Cytoscape 3.7.2 was used for visualization of the generated molecular networks (Shannon *et al.*, 2003). A network representing the ions detected in the crude extract of *Streptomyces* sp. MBT27 grown with 1% glycerol was constructed, revealing 172 nodes clustered in 10 spectral families (Figure 2). The molecular network revealed an actinomycin spectral family containing actinomycin D, X_2 and $X_{0\beta}$. Moreover, the same spectral family included a yet unidentified compound with m/z 1387.67. It was closely connected (cosine score > 0.7) to the known actinomycins, suggesting that the molecule was a novel actinomycin. Statistical analysis showed that the extracts with stronger antimicrobial activity contained higher concentrations of actinomycins X_2 , $X_{0\beta}$, D and the

new compound, in comparison with the less active ones (ANOVA, $p < 0.05$; Figure 2). It is important to note that actinomycins were only detected in the bioactive extracts.





Figure 2. GNPS molecular network of the ions detected in the crude extract of *Streptomyces* sp. MBT27. Cultures were grown for seven days in MM with 1% glycerol. Orange nodes represent ions of the metabolites produced by *Streptomyces* sp. MBT27, while blue nodes represent those of the media components. The actinomycin spectral family is enlarged. Results of ANOVA statistical analysis were mapped onto the molecular network to illustrate the differential production of actinomycin cluster members under various growth conditions. Box plots represent relative intensities of actinomycins X₂, X₀₈, and D after log transformation and pareto scaling; together with a compound with an m/z value of 1387.67, in cultures grown in MM with the following carbon sources: 1. 1% arabinose; 2. 1% fructose; 3. 1% GlcNAc; 4. 1% glucose; 5. 2% glucose; 6. 1% glycerol; 7. 2% glycerol; 8. 1% mannitol; 9. 1% mannitol + 1% glycerol; 10. 2% mannitol (%ages in w/v).

Large scale fermentation and NMR

To allow identification and structural analysis of the likely novel actinomycin analog, we performed large-scale fermentation of *Streptomyces* sp. MBT27 followed by bioactivity-guided fractionation. The purification process resulted in the isolation of two compounds

(1) and (2), with the same mass (Figures S4, S5). The NMR spectra of the two compounds were very similar, suggesting that they were diastereomers (Figures S6-S12). Based on 1D and 2D NMR analysis of **1**, together with the molecular formula and degrees of unsaturation dictated by the accurate mass, the structure of the isolated diastereomers was determined as a variant of actinomycin D, whereby an amination was formed between the amino group of anthranilamide moiety and keto group at the γ position of the proline residues (Figure 3). The prolyl substitution position is the same as that of the hydroxyl and keto groups in actinomycins $X_{0\beta}$ and X_2 , respectively. The new actinomycin analog was designated actinomycin L (with L standing for Leiden, the city of its discovery).



As the absolute configuration of the amino acid residues in **2** was consistent with that of previously reported actinomycins (Wang *et al.*, 2017), and considering that the two isomers stemmed from the amination at C-10', compound **1** is inevitably the 10'S isomer of actinomycin L.

Biosynthesis of actinomycin L

Actinomycins D (or X_1), X_2 , and $X_{0\beta}$ detected in the extracts of *Streptomyces* sp. MBT27 are members of the actinomycin X complex. Recently it was shown that actinomycins $X_{0\beta}$ and X_2 are formed through the sequential oxidation of the γ -prolyl carbon by the cytochrome P450 enzyme saAcM (Semsary *et al.*, 2018, Liu *et al.*, 2017). Based on its structure, actinomycin L is most likely formed through an amination reaction between the two amino groups of anthranilamide and the γ -keto group on the proline residue of actinomycin X_2 . Accordingly, its production should be arrested when one of the precursors is not available. Interestingly, *Streptomyces* sp. MBT27 produced actinomycin L in very low amounts when grown with fructose (1% w/v) as the sole carbon source. Moreover, ANOVA statistical analysis showed that anthranilamide was produced in equally low amounts under the same growth conditions (ANOVA, $p < 0.05$; Figure 5). Under conditions where *Streptomyces* sp. MBT27 produced actinomycin L, namely when grown in MM with 1% GlcNAc, 1% glucose, 1% glycerol, 2% glycerol or in 1% mannitol + 1% glycerol, the strain invariably produced both actinomycin X_2 and anthranilamide. However, under conditions where actinomycin X_2 was produced but not anthranilamide, the strain failed to produce actinomycin L (Figure 5).

We, therefore, wondered if anthranilamide may be a precursor for the biosynthesis of actinomycin L. To test this hypothesis, we performed a feeding experiment, whereby anthranilamide was added to cultures of *Streptomyces* sp. MBT27 grown in MM with 1% fructose, where virtually no actinomycin L was produced. Analysis of the supernatant of the cultures via LC-MS revealed that actinomycin L was readily produced when anthranilamide was added, but not without it (Figure 6A). This strongly suggested that anthranilamide is required for the production of actinomycin L. However, extracts of *Streptomyces* sp. MBT27 fermented with 1% fructose and additional anthranilic acid contained both anthranilamide and actinomycin L (Figure 6A). This suggests that indeed anthranilic acid is converted into anthranilamide, which in turn is incorporated into actinomycin L.




Figure 5. Box plots showing the relative intensities of actinomycin L₁, L₂ and X₂ and anthranilamide after log transformation and pareto scaling. Cultures of *Streptomyces* sp. MBT27 were grown for seven days in MM with the following carbon sources: 1. 1% arabinose; 2. 1% fructose; 3. 1% GlcNAc; 4. 1% glucose; 5. 2% glucose; 6. 1% glycerol; 7. 2% glycerol; 8. 1% mannitol; 9. 1% mannitol + 1% glycerol; 10. 2% mannitol (% ages in w/v). Red box indicates the abundance of actinomycin L₁, L₂ and X₂ and anthranilamide in the cultures grown with fructose (1% w/v). Note that *Streptomyces* sp. MBT27 produced actinomycin L and anthranilamide in very low amounts when fermented with fructose (1% w/v) as the sole carbon source.




Figure 6. Anthranilamide is required for the biosynthesis of actinomycins L₁ and L₂. Box plots show the relative intensities of actinomycin L₁ and L₂ after log transformation and pareto scaling in the cultures of *Streptomyces* sp. MBT27 (A) and *S. antibioticus* (B) fermented for seven days in MM with fructose (1% w/v) (1), fed with 0.7 mM anthranilamide (2) and 0.7 mM anthranilic acid (3). Note that *S. antibioticus* produces actinomycin L exclusively in the presence of anthranilamide and not with anthranilic acid; conversely, *Streptomyces* sp. MBT27 is able to convert anthranilic acid into anthranilamide, enabling the production of actinomycin L.

In order to unambiguously verify that actinomycin L was the product of anthranilamide and actinomycin X_2 , we conducted another biotransformation experiment, now feeding anthranilamide to *S. antibioticus* IMRU 3720, which is a known producer of actinomycins X_2 and $X_{0\beta}$, but fails to produce actinomycin L under any condition tested. In line with our hypothesis, *S. antibioticus* IMRU 3720 also failed to produce anthranilamide under any of the growth conditions (Figure S13). Excitingly, LC-MS analysis revealed the production of actinomycin L by *S. antibioticus* IMRU 3720 when anthranilamide was fed to the cultures, but never without anthranilamide (Figure 6B). This validates the concept that anthranilamide is a key precursor of actinomycin L. Conversely, when anthranilic acid instead of anthranilamide was added to cultures of *S. antibioticus* IMRU 3720, we failed to detect actinomycin L and anthranilamide (Figure 6B).

The oxidation of the proline residue in actinomycins $X_{0\beta}$ and X_2 occurs following the formation of the two halves of actinomycin, known as 4-MHA PPLs, and prior to the condensation of these halves to form actinomycin (Semsary *et al.*, 2018). Taking this into account, we reasoned that anthranilamide should be incorporated into the actinomycin halves prior to condensation. To check this, 3-hydroxy-4-methylbenzoic acid (4-MHB) was added to cultures of *Streptomyces* sp. MBT27 and of *S. antibioticus* IMRU 3720. 4-MHB is a structural analog of 4-MHA that replaces 4-MHA as a starter unit in the nonribosomal assembly of the actinomycin halves (Semsary *et al.*, 2018). When 4-MHB replaces 4-MHA, 4-MHB containing PPLs accumulate because they cannot react with each other to give a phenoxazinone ring, as is the case with 4-MHA PPLs (Keller, 1984). LC-MS analysis of the 4-MHB-supplemented extracts showed the appearance of the previously reported 4-MHB-containing pentapeptide lactones PPL 1, PPL 0, and PPL 2, and new PPL, designated as PPL 3 (Figures S14–S17, Table S1). The exact mass and fragmentation pattern of PPL 3 was consistent with a 4-MHB containing PPL wherein an anthranilamide moiety had been attached to the proline residue (Figure S17).

Taken together, the feeding experiments convincingly show that actinomycin L is formed through the reaction of anthranilamide with the 4-keto group on the proline residue in the pentapeptide lactone. Moreover, results of the feeding experiments with 3-hydroxy-4-methylbenzoic acid show that this reaction occurs prior to the condensation of the pentapeptide lactones into actinomycin L (Figure 7).




Figure 7. Proposed biosynthetic pathway for actinomycin L. We propose that actinomycin L is formed through the reaction of anthranilamide (blue) with the 4-oxoproline moiety of actinomycin X₂ prior to the condensation of two 4-MHA PPLs into the actinomycin L.

Identification of the actinomycin BGC in *Streptomyces* sp. MBT27

To characterize the BGC responsible for actinomycin biosynthesis and compare the genes with those found in known actinomycin BGCs, *Streptomyces* sp. MBT27 was sequenced using the PacBio platform (GenBank accession number: PRJNA602665). Assembly of the PacBio reads resulted in two contigs of 8.4 Mb and 0.13 Mb in length. Analysis using AntiSMASH 6 (Blin *et al.*, 2021) readily identified the actinomycin BGC in the 8.4 Mb contig. A comparison with the actinomycin X₂ BGC from *S. antibioticus* showed that all genes were highly conserved between the two clusters (Table S2, Figure S18). This strongly suggests that the actinomycin BGC does not specify the observed modifications in the actinomycin structure, and is not responsible for the production of anthranilamide. We have not yet identified the enzyme for the predicted conversion of anthranilic acid to anthranilamide.

Bioactivity of isolated compounds (MIC)

Bioactivity assays were carried out for the actinomycins, to test their ability to act as antibiotics. As expected, the compounds showed selective antibacterial activity against Gram-positive pathogens, and none of the actinomycins presented any activity against *E. coli* ATCC 25922 or *K. pneumoniae* ATCC 700603 (Table 1). All tested compounds showed antibacterial activity against Gram-positive bacteria with MIC values ranging from 1 to 16 µg/mL. Actinomycin L₁ showed somewhat higher bioactivity than actinomycin L₂, while both compounds showed slightly higher MICs than actinomycin D and Actinomycin X₂.

Table 1. Antibacterial activities of compounds expressed as minimal inhibitory concentrations (MIC)*.

Strain	Actinomycin X ₂	Actinomycin D	Actinomycin L ₁	Actinomycin L ₂
<i>S. aureus</i> MB5393 (methicillin-resistant)	2-4	1-2	4-8	8-16
<i>S. aureus</i> ATCC 29213 (methicillin-sensitive)	1-2	1-2	2-4	n.a.
<i>E. faecium</i> (vancomycin-sensitive)*	1-2	1-2	4-8	8-16
<i>E. faecium</i> VanB (vancomycin-resistant)*	1-2	1-2	4-8	8-16
<i>S. epidermidis</i> *	2-4	2-4	4-8	n.a.
<i>E. coli</i> ATCC 25922	>128	>128	>128	n.a
<i>K. pneumoniae</i> ATCC 700603	>128	>128	>128	n.a

(*), clinical isolates; n.a.: data not available. * all concentrations given in µg/mL.

Discussion

Actinomycin was the first antibiotic identified in Actinobacteria (Waksman & Woodruff, 1940). The well-established actinomycin structure is composed of a heterocyclic chromophore and two cyclic PPLs. Biosynthetically, PPL is biosynthesized by an NRPS assembly line with the 4-MHA as the initiating unit (Jones, 1987, Pfennig *et al.*, 1999). 4-MHA is derived from 3-hydroxy-4-methylkynurenine (4-MHK), which is formed by methylation of 3-hydroxykynurenine (3-HK) (Crnovcic *et al.*, 2017). Our work surprisingly revealed a novel structure within the extensively studied actinomycin family, namely that of actinomycin L, which arises via attachment of an anthranilamide moiety to the γ -carbon of one of the proline residues through amination. ANOVA statistical analysis proved that production of anthranilamide is the limiting factor in the biosynthesis of actinomycin L. Feeding experiments with anthranilamide suggested that actinomycin L is formed through the spontaneous reaction of anthranilamide with the 4-oxoproline site of actinomycin X₂ prior to the condensation of the two 4-MHA PPLs into actinomycin L. To the best of our knowledge, the attachment of anthranilamide to a 4-oxoproline moiety is a novel observation.

The actinomycin BGC of *Streptomyces* sp. MBT27 harbors the same genes as that of *S. antibioticus*, with high homology between the genes, which strongly suggests that the modification of actinomycin X₂ to actinomycin L is not encoded by the BGC itself. Indeed, we anticipate that anthranilamide is derived from anthranilic acid in *Streptomyces* sp. MBT27, whereby anthranilic acid in turn is biosynthesized through the shikimate pathway (Dewick, 2009). Anthranilic acid is a commonly produced primary metabolite in *Streptomyces*, while anthranilamide is less common (Shaaban *et al.*, 2012a, Biabani *et al.*, 1998, Ham & Kim, 2018). The actinomycin X₂ producer *S. antibioticus* IMRU 3720 fails to convert anthranilic acid into anthranilamide, which explains why actinomycin L was also not detected in the extracts. However, actinomycin L was produced when we fed cultures of *S. antibioticus* IMRU 3720 with additional anthranilamide, which is fully in line with our proposed biosynthetic pathway. Thus, actinomycin L is an example of a natural product that requires the joining of two separate metabolic pathways, and this is a concept that needs more attention. After all, scientists rely increasingly on heterologous expression and synthetic biology approaches (Kolter & van Wezel, 2016), and these will likely fail if genes are required that do not fall within the main BGC.

The production of actinomycins by *Streptomyces* spp. is strongly influenced by the carbon source, whereby the preferred carbon source varies from strain to strain (Katz *et al.*, 1957, Haque *et al.*, 1995, Theobald *et al.*, 2000, Dalili & Chau, 1988, Williams & Katz, 1977). D-galactose favors actinomycin production in *Streptomyces antibioticus* over arabinose, xylose, glucose, fructose and rhamnose (Katz *et al.*, 1957), while glycerol was the optimal carbon source for actinomycin production by *S. antibioticus* Tü 6040 and *S. antibioticus* SR15.4

(Theobald *et al.*, 2000, Haque *et al.*, 1995). In the case of *Streptomyces* sp. MBT27, growth on MM with glycerol, GlcNAc, fructose and glucose (all 1% w/v) as sole carbon sources were the best carbon sources to promote the production of actinomycins. However, increasing the glucose concentration to 2% blocked the production of actinomycins. Glucose was previously reported to repress the transcription of the gene for hydroxykynureninase, which is involved in the formation of the main actinomycin precursor 4-MHA (Katz *et al.*, 1957). Importantly, in our experiments the carbon source not only promoted the overall production levels, but also contributed to the chemical diversity of the actinomycins, including the production of actinomycin L. This coincided with the production of anthranilamide, an essential substrate to form this novel actinomycin variant.

In the 21st century, genome mining and renewed drug discovery efforts have revealed that Actinobacteria may produce many more molecules than was expected (Nett *et al.*, 2009). What is important to note is that this also applies to well-known families of molecules and in extensively studied model organisms. Examples are the highly rearranged cryptic polyketide lugdunomycin that belongs to the family of angucyclines (Wu *et al.*, 2019), the new glycopeptide corbomycin with a novel mode of action (Culp *et al.*, 2020), as well as the discovery of coelimycin (Gomez-Escribano *et al.*, 2012) and a novel branch of the actinorhodin biosynthetic pathway (Wu *et al.*, 2017) in the model organism *Streptomyces coelicolor*. The discovery of actinomycin L provides another interesting example that we have not yet exhausted the known part of the chemical space. Indeed, the isolation of these novel actinomycins underlines that the biosynthetic potential of Actinobacteria still has major surprises in store, and that we can expect that new molecules can be discovered even within extensively studied microbes and compound classes.

Materials and Methods

General experimental procedures

Optical rotation, FT-IR and UV were measured as previously described (Elsayed *et al.*, 2020). NMR spectra were recorded on a Bruker Ascend 850 MHz NMR spectrometer (Bruker BioSpin GmbH). Data was analyzed using MestReNova 14 software (Mestrelab Research, Santiago de Compostela, Spain). The structures of molecules were drawn using ChemDraw Professional version 16.0 (Perkin-Elmer Informatics). HPLC purification was performed on Waters preparative HPLC system as described (Machushynets *et al.*, 2019). All solvents and chemicals were of HPLC or LC-MS grade, depending on the experiment.

Bacterial strains, growth conditions and metabolite extraction

Streptomyces sp. MBT27 was obtained from the Leiden University strain collection and had previously been isolated from the Qingling Mountains, Shanxi province, China (Zhu *et al.*, 2014a). Cultures were grown in triplicate in 100 mL Erlenmeyer flasks containing 30 mL of liquid minimal medium (MM) (Kieser, 2000), supplemented with various carbon sources, and inoculated with 10 μ L of 10^9 /mL spore suspension. The carbon sources (percentages in w/v) were: 1% mannitol+1% glycerol, 1% mannitol, 2% mannitol, 1% glycerol, 2% glycerol, 1% glucose, 2% glucose, 1% fructose, 1% arabinose or 1% *N*-acetylglucosamine (GlcNAc). The cultures were incubated in a rotary shaker at 30 °C and 220 rpm for seven days. Following fermentation, culture supernatants were extracted with ethyl acetate (EtOAc) and evaporated under reduced pressure. In the series of feeding experiments *Streptomyces* sp. MBT27, *S. antibioticus* IMRU 3720 and *S. chrysomallus* ATCC11523 were fermented in MM supplemented with 1% fructose and 0.7 mM anthranilamide. For the directed biosynthesis of non-natural actinomycin X halves *Streptomyces* sp. MBT27 and *S. antibioticus* IMRU 3720 were grown in MM with 1% w/v fructose, 0.7 mM anthranilamide and 0.7 mM 3-hydroxy-4-methylbenzoic acid (4-MHB) and extracted with EtOAc.

Genome sequencing, assembly and annotation

Streptomyces sp. MBT27 was grown in YEME at 30 °C and 220 rpm for 48 hours. DNA was extracted from *Streptomyces* sp. MBT27 as described (Kieser, 2000). DNA quality was verified by agarose gel electrophoresis. PacBio sequencing and assembly was performed by Novogene (UK). Generally, library was prepared using SMRTbell template prep kit (PacBio, USA) according to manufacturer instructions. Sequencing was then performed using PacBio Sequel platform in continuous long reads mode. Assembly was done using Flye (version 2.8.1) (Kolmogorov *et al.*, 2019). Biosynthetic gene clusters (BGCs) in this genome were annotated using AntiSMASH 6.0 (Blin *et al.*, 2021). The actinomycin BGC was then extracted

and compared with the same cluster from *S. antibioticus* IMRU 3720 using clinker version 0.0.20) with default settings (Gilchrist & Chooi, 2021).

Up-scale fermentation, extraction and fractionation

Large-scale fermentation, extraction and fractionation were performed as previously described (Machushynets *et al.*, 2019). The fractions eluted with *n*-hexane–acetone (1:1) was subjected to a SunFire C₁₈ column (10 μm, 100 Å, 19×150 mm) eluted with a H₂O–MeOH gradient of 50–100% in 20 min, at a flow rate of 15 mL/min. The fraction containing the actinomycins was collected and further purified on semi-preparative SunFire C₁₈ column (5 μm, 100 Å, 10×250 mm), run at 3 mL/min, and eluted using a H₂O–MeOH gradient of 70–100% in 20 min, to yield actinomycins L₁ (1, 2.9 mg), L₂ (2, 1.3 mg), X₂ (3, 1 mg), X₀₈ (4, 2.9 mg), and D (5, 3.2 mg).

Actinomycin L₁ (1): red amorphous powder; $[\alpha]_D^{25}$ -38 (c 0.2, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 211 (1.957), 312 (0.124), 427.5 (0.152), 438 (0.151) nm; IR $\nu_{\max}$ 3301, 2963, 2921, 2859, 1740, 1662, 1644, 1585, 1521, 1465, 1405, 1300, 1262, 1191, 1097 cm⁻¹; ¹H and ¹³C NMR data, see Table 2; HRESIMS (positive mode) m/z 1387.6681 [M+H]⁺ (calcd. for C₆₉H₉₁N₁₄O₁₇, 1387.6681).

Actinomycin L₂ (2): red amorphous powder; $[\alpha]_D^{25}$ -54 (c 0.2, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 226 (2.189), 364 (0.186) nm, 426.5 (0.367) nm; IR $\nu_{\max}$ 3308, 2943, 2929, 2831, 1748, 1662, 1644, 1585, 1448, 1406, 1302, 1262, 1191, 1113 cm⁻¹; HRESIMS (positive mode) m/z 1387.6674 [M+H]⁺ (calcd. for C₆₉H₉₁N₁₄O₁₇, 1387.6681). The X-ray diffraction experiment on a crystal grown from MeOH further confirmed the structure and determined the absolute configuration of compound 2 (Figure 4) (CCDC 2110000). Structure visualization and image preparation was done using Mercury version 4.3.0 (Macrae *et al.*, 2020).

Table 2. ^1H and ^{13}C NMR data of **1** in CDCl_3 at 298 K^[a].

Position	δ_{C} , type	δ_{H} , mult. (<i>J</i> in Hz)	Position	δ_{C} , type	δ_{H} , mult. (<i>J</i> in Hz)
1	129.5, C		22'	167.4, C	
2	130.9, C		23'	74.5, CH	5.29, qd (6.3, 3.1)
3	125.9	7.75, m	24'	17.5, CH_3	1.23, d (6.3)
4	130.0, CH	7.44, dd (7.6, 0.9)	25'	163.1, C	
5	128.5, C		26'	114.3, C	
6	140.6, C		27'	128.6, CH	7.90, dd (7.9, 1.6)
7	144.7, C		28'	118.7, CH	6.81, dt (0.9, 7.9)
8	113.6, C		29'	133.6, CH	7.30, dt (1.6, 7.9)
9	178.9, C		30'	113.9, CH	6.67, dd (7.9, 0.9)
10	ND		31'	146.7, C	
11	ND		1''	166.4, C	
12	ND		2''	55.5, CH	4.69, dd (6.6, 2.7)
13	15.1, CH_3	2.58, d (0.9)	NH-2''		7.64, d (6.6)
14	7.7, CH_3	2.26, s	3''	168.6, C	
1'	166.1, C		4''	58.6, CH	3.57, m
2'	54.7, CH	4.45, dd (6.4, 3.1)	NH-4''		7.75, m
NH-2'		7.38, d (6.4)	5''	31.8, CH	2.10, m
3'	168.7, C		6''	18.9, CH_3	1.10, d (6.7)
4'	57.9, CH	3.56, m	7''	19.2, CH_3	0.91, d (6.7)
NH-4'		8.28, d (5.4)	8''	ND	
5'	31.0, CH	2.17, m	9''	47.5, CH_2	3.82, m 3.75, m
6'	18.8, CH_3	1.13, d (6.7)	10''	22.8, CH_2	2.29, m 2.07, m
7'	19.1, CH_3	0.87, d (6.7)	11''	31.1, CH_2	2.84, m 1.86, dd (11.9, 6.9)
8'	ND		12''	56.3, CH	5.95, d (9.2)
9'	60.5, CH_2	4.49, d (13.4) 4.07, d (13.4)	13''	172.9, C	
10'	76.8, C		14''	34.9, CH_3	2.89, s
11'	43.1, CH_2	2.94, m 2.25, m	15''	51.3, CH_2	4.72, d (17.1) 3.65, d (17.1)
12'	56.7, CH	6.27, d (10.5)	16''	165.4, C	
13'	173.1, C		17''	39.4, CH_3	2.93, s
14'	35.1, CH_3	2.93, s	18''	71.4, CH	2.70, m
15'	51.1, CH_2	4.36, d (17.1) 3.58, d (17.1)	19''	27.0, CH	2.69, m
16'	166.3, C		20''	19.0, CH_3	0.75, d (6.3)
17'	39.1, CH_3	2.95, s	21''	21.7, CH_3	0.98, d (6.0)
18'	71.3, CH	2.67, m	22''	167.2, C	
19'	26.9, CH	2.65, m	23''	75.2, CH	5.22, qd (6.3, 2.7)
20'	19.0, CH_3	0.75, d (6.8)	24''	17.9, CH_3	1.30, d (6.3)
21'	21.6, CH_3	0.96, d (6.4)			

^[a] ^1H 850 MHz and ^{13}C NMR resonances inferred from HSQC and HMBC spectra.

Single crystal X-ray crystallography

All reflection intensities were measured at 100(2) K using a SuperNova diffractometer (equipped with Atlas detector) with Cu K α radiation ($\lambda = 1.54178 \text{ \AA}$) under the program CrysAlisPro (Version CrysAlisPro 1.171.39.29c, Rigaku OD, 2017). The same program was used to refine the cell dimensions and for data reduction. The structure was solved with the program SHELXS-2018/3 and was refined on F^2 with SHELXL-2018/3 (Sheldrick, 2015). Analytical numeric absorption correction using a multifaceted crystal model was applied using CrysAlisPro. The temperature of the data collection was controlled using the system Cryojet (manufactured by Oxford Instruments). Prior to mounting the chosen single crystal on the diffractometer, crystals were placed in some Parabar 10312 on a microscope slide and cooled via a cold N₂(g) stream in order to protect the crystal from potential solvent loss. The H atoms were placed at calculated positions (unless otherwise specified) using the instructions AFIX 13, AFIX 23, AFIX 43, AFIX 137 or AFIX 147 with isotropic displacement parameters having values 1.2 or 1.5 U_{eq} of the attached C or O atoms. The H atoms attached to N2, N1', N2', N6', N7', N1'' and N2'' were found from difference Fourier maps, and their coordinates were refined pseudofreely using the DFIX instruction in order to keep the N–H bonds within an acceptable range. The structure is partly disordered. The asymmetric unit contains one molecule of the target compound as well as some significant amount of lattice MeOH solvent molecules. Six solvent molecules were modelled as ordered with four being fully occupied and two with partial occupancy factors of 0.918(11) and 0.487(10). The contribution of the remaining amount of disordered lattice solvent molecules has been removed using the SQUEEZE procedure in Platon (Spek, 2009). Furthermore, the atoms C9'', C10'' and C11'' are disordered over two orientations, and the occupancy factor of the major component of the disorder refines to 0.533(10). The absolute configuration has been established by anomalous-dispersion effects in diffraction measurements on the crystal, and the Flack and Hooft parameters refine to 0.08(5) and 0.06(5), respectively. The model has chirality S, S, R, R, R, S, S, S, R, R at C2', C2'', C4', C4'', C10', C12', C18', C18'', C23', C23'', respectively. Structure visualization and image preparation was done using Mercury (Macrae *et al.*, 2020).

Antimicrobial activity assay and MIC determination

The antimicrobial activity of the compounds was tested in liquid inhibition assays against seven pathogens including Gram-negative and Gram-positive bacteria (*Escherichia coli* ATCC25922, *Klebsiella pneumoniae* ATCC700603, methicillin-resistant *Staphylococcus aureus* MB5393, methicillin-sensitive *Staphylococcus aureus* ATCC29213, linezolid-resistant *Staphylococcus epidermidis* (clinical isolate), vancomycin-sensitive *Enterococcus faecium* (clinical isolate), and vancomycin-resistant *Enterococcus faecium* VanB (clinical isolate), as described (Audoin *et al.*, 2013). Each compound was serially diluted in DMSO with a dilution

factor of 2 to test 10 concentrations starting at 128 µg/mL in all the antimicrobial assays. The MIC was defined as the lowest concentration of compound that inhibited $\geq 95\%$ of the growth of a microorganism after overnight incubation. The Genedata Screener software (Genedata, Inc., Basel, Switzerland) was used to process and analyze the data and to calculate the RZ' factor in the assay that was between 0.90 and 0.98 supporting its robustness.

LC-MS/MS analysis

For LC-MS analyses, extracts were dissolved in MeOH to a final concentration of 1 mg/mL, and 1 µL was injected into Waters Acquity UPLC system coupled to Agilent 6530 QTOF MS. Samples were analyzed according to the protocol that was previously published (Machushynets *et al.*, 2019). LC-MS/MS acquisition of the pure compounds was performed using Shimadzu Nexera X2 UHPLC system coupled to Shimadzu 9030 QTOF mass spectrometer as previously described (Xiao *et al.*, 2020). LC-MS/MS acquisition for molecular networking was performed using Thermo Instruments MS system (LTQ Orbitrap XL, Bremen, Germany) equipped with an electrospray ionization source (ESI) as described (Machushynets *et al.*, 2019).

Computation of mass spectral networks

MS/MS raw data were converted to a 32-bit mzXML file using MSConvert (ProteoWizard) (Chambers *et al.*, 2012) and spectral networks were assembled using Global Natural Product Social molecular networking (GNPS) (<https://gnps.ucsd.edu>) as described (Wang *et al.*, 2016). Briefly, the precursor ion mass tolerance was set to 2.0 Da and a MS/MS fragment ion tolerance of 0.5 Da, while the minimum cosine score was set to 0.7. The data were clustered using MSCluster with a minimum cluster size of three spectra. The spectra in the network were also searched against GNPS spectral libraries. A minimum score of 0.7 was set for spectral library search, with at least six fragment peaks matching. Cytoscape 3.7.2 was used for visualization of the generated molecular networks (Shannon *et al.*, 2003). In Cytoscape the detected chemical space is displayed as nodes and edges (nodes correspond to a specific consensus spectrum; edges represent significant pairwise alignment between nodes). The edge thickness was set to represent the cosine score, with thicker lines indicating higher similarity between nodes. LC-MS/MS data were deposited in the MassIVE Public GNPS data set (MSV000085106). The molecular networking job in GNPS can be found at <https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=0c9153470404488d8927289139f875d3>. The annotated MS/MS spectra were deposited in the GNPS spectral library for actinomycin L₁ (CCMSLIB00005718892) and L₂ (CCMSLIB00005718891).

Statistical analysis

Prior to statistical analysis, mzXML files, which were converted using Shimadzu LabSolutions Postrun Analysis, were imported into Mzmine 2.31 (Pluskal *et al.*, 2010) and processed as

previously described (Machushynets *et al.*, 2019). The aligned peak list was exported as a comma-separated file for statistical analysis. Statistical analysis was performed using MetaboAnalyst (Chong *et al.*, 2018), where log transformation and pareto scaling was initially applied to the data. The normalized data were subjected to principal components analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). The quality of the models was evaluated with the relevant R^2 and Q^2 . To identify the difference in intensity of a single mass feature among multiple growth conditions, one-way ANOVA was performed, followed by a *post hoc* Tukey's honest significant difference (HSD) test.

Acknowledgments

The work was supported by the NACTAR program of The Netherlands Organization for Scientific Research (NWO), Grant 16440 to G.P.vW., M.H.M. and N.I.M.

Supplementary information

Table S1. Accurate mass of [M+H]⁺ and product ions of the PPLs analyzed by ESI-QTOF MS/MS.

Compound	Scan #, t _R (min)	Composition	Proposed ion	Measurement (m/z)	Calculated (m/z)	Difference (ppm)
PPL0	2973 @5.29	C ₃₁ H ₄₆ N ₅ O ₉	[M+H] ⁺	632.3170	632.3295	-18.99
		C ₃₁ H ₄₄ N ₅ O ₈	[M+H-H ₂ O] ⁺	614.3177	614.3189	-1.2
		C ₂₅ H ₃₃ N ₄ O ₇	[M+H-(H-MeVal-OH)] ⁺	501.2347	501.2349	0.65
		C ₂₂ H ₂₈ N ₃ O ₆	[M+H-(H-Sar-MeVal-OH)] ⁺	430.1969	430.1978	-0.84
		C ₁₉ H ₃₃ N ₄ O ₆	[(H-Val-OxoPro-Sar-MeVal-OH)+H] ⁺	415.2552	415.2556	0.214
		C ₁₉ H ₃₃ N ₄ O ₅	[(H-Val-OxoPro-Sar-MeVal-OH)+H-H ₂ O] ⁺	397.2441	397.2450	-1.124
		C ₁₄ H ₂₆ N ₃ O ₅	[(H-Hyp-Sar-MeVal-OH)+H] ⁺	316.1870	316.1872	0.957
		C ₁₄ H ₂₄ N ₃ O ₄	[(H-Hyp-Sar-MeVal-OH)+H-H ₂ O] ⁺	298.1761	298.1766	-0.110
		C ₁₃ H ₂₂ N ₃ O ₄	[(H-Val-HypPro-Sar)+H] ⁺	284.1606	284.1610	0.413
		C ₁₂ H ₁₂ NO ₃	[M+H-(H-Val-Hyp-Sar-MeVal-OH)] ⁺	218.0816	218.0817	1.973
				213.1233		
		C ₉ H ₁₉ N ₂ O ₃	[(H-Sar-MeVal-OH)+H] ⁺	203.1391	203.1395	0.399
		C ₆ H ₁₄ NO ₂	[(H-MeVal-OH)+H] ⁺	132.1015	132.1024	-3.067
		C ₄ H ₆ NO ₂	[Thr+H] ⁺	100.0389	100.0398	-4.048

PPL1	#3129 @5.60	$C_{31}H_{46}N_5O_8$	$[M+H]^+$	616.3326	616.3346	-2.417
		$C_{31}H_{44}N_5O_7$	$[M+H-H_2O]^+$	598.3248	598.3241	2.131
		$C_{25}H_{33}N_4O_6$	$[M+H-(H-MeVal-OH)]^+$	485.2392	485.2400	-0.538
		$C_{22}H_{28}N_3O_5$	$[M+H-(H-Sar-MeVal-OH)]^+$	414.2025	414.2028	0.368
		$C_{19}H_{21}N_2O_4$	$[(H-Val-Pro-Sar-MeVal-OH)+H]^+$	399.2607	399.2607	1.261
		$C_{19}H_{33}N_4O_4$	$[(H-Val-Pro-Sar-MeVal-OH)+H-H_2O]^+$	381.2504	381.2501	2.014
		$C_{17}H_{21}N_2O_4$	$[M+H-(H-Pro-Sar-MeVal-OH)]^+$	317.1496	317.1501	0.052
		$C_{14}H_{26}N_3O_4$	$[(H-Pro-Sar-MeVal-OH)+H]^+$	300.1916	300.1923	-0.609
		$C_{14}H_{24}N_3O_3$	$[(H-Pro-Sar-MeVal-OH)+H-H_2O]^+$	282.1809	282.1817	-1.127
		$C_{13}H_{22}N_3O_3$	$[(H-Val-Pro-Sar)+H]^+$	268.1657	268.1661	0.492
		$C_9H_{19}N_2O_3$	$[(H-Sar-MeVal-OH)+H]^+$	203.1392	203.1395	0.891
				187.1078		
		$C_8H_{13}N_2O_2$	$[(H-Pro-Sar)+H]^+$	169.0968	169.0977	-2.095
		$C_6H_{14}NO_2$	$[(H-MeVal-OH)+H]^+$	132.1016	132.1024	-2.310
		$C_4H_6NO_2$	$[Thr+H]^+$	100.0391	100.0398	-2.049

PPL2	#3708 @6.60	$C_{31}H_{44}N_5O_9$	$[M+H]^+$	630.3132	630.3139	-0.245
		$C_{31}H_{42}N_5O_8$	$[M+H-H_2O]^+$	612.3027	612.3033	-0.146
			?? $[M+H-CO]^+$	602.5191		
		$C_{25}H_{33}N_4O_8$	$[M+H-(H-MeVal)]^+$	517.2286	517.2298	-1.335
		$C_{25}H_{31}N_4O_7$	$[M+H-(H-MeVal-OH)]^+$	499.2190	499.2192	0.549
		$C_{22}H_{26}N_3O_6$	$[M+H-(H-Sar-MeVal-OH)]^+$	428.1814	428.1821	-0.495
		$C_{19}H_{33}N_4O_6$	$[(H-Val-OxoPro-Sar-MeVal-OH)+H]^+$	413.2395	413.2400	0.094
		$C_{19}H_{31}N_4O_5$	$[(H-Val-OxoPro-Sar-MeVal-OH)+H-H_2O]^+$	395.2293	395.2294	1.021
		$C_{14}H_{24}N_3O_5$	$[(H-OxoPro-Sar-MeVal-OH)+H]^+$	314.1711	314.1715	0.168
				300.1555		
		$C_{14}H_{22}N_3O_4$	$[(H-Val-OxoPro-Sar-MeVal-OH)+H-H_2O]^+$	296.1605	296.1610	0.059
		$C_{13}H_{20}N_3O_4$	$[(H-Val-OxoPro-Sar)+H]^+$	282.1448	282.1453	-0.116
		$C_{12}H_{12}NO_3$	$[M+H-(H-Val-Hyp-Sar-MeVal-OH)]^+$	218.0815	218.0817	1.514
		$C_9H_{19}N_2O_3$	$[(H-Sar-MeVal-OH)+H]^+$	203.1391	203.1395	0.399
				183.0761		
		$C_6H_{14}NO_2$	$[(H-MeVal-OH)+H]^+$	132.1017	132.1024	-1.554
		$C_4H_6NO_2$	$[Thr+H]^+$	100.0391	100.0398	-2.049

PPL3	#3312	$C_{38}H_{50}N_7O_9$	$[M+H]^+$	748.3663	748.3670	-0.204
	@5.96	$C_{38}H_{48}N_7O_8$	$[M+H-H_2O]^+$	730.3561	730.3564	0.290
				702.3638		
		$C_{32}H_{37}N_6O_7$	$[M+H-(H-MeVal-OH)]^+$	617.2716	617.2723	-0.363
				596.3200		
		$C_{26}H_{39}N_6O_6$	$[(H-Val-AntPro-Sar-MeVal-OH)+H]^+$	531.2928	531.2931	0.453
		$C_{26}H_{37}N_6O_5$	$[(H-Val-AntPro-Sar-MeVal-OH)+H-H_2O]^+$	513.2820	513.2825	0.010
				485.2873		
		$C_{21}H_{30}N_5O_5$	$[(H-AntPro-Sar-MeVal-OH)+H]^+$	432.2247	432.2246	1.283
		$C_{21}H_{28}N_5O_4$	$[(H-AntPro-Sar-MeVal-OH)+H-H_2O]^+$	414.2137	414.2141	0.288
		$C_{20}H_{26}N_5O_4$	$[(H-Val-AntPro-Sar)+H]^+$	400.1982	400.1984	0.673
		$C_{17}H_{21}N_4O_3$	$[(H-Val-AntPro)+H]^+$	329.1607	329.1613	
		$C_{17}H_{21}N_2O_4$	$[M+H-(H-Pro-Sar-MeVal-OH)]^+$	317.1493	317.1501	-0.894
		$C_{15}H_{17}N_4O_3$	$[(H-Pro-Sar)+H]^+$	301.1295	301.1300	-0.056
				284.1032		
				230.0925		
		$C_9H_{19}N_2O_3$	$[(H-Sar-MeVal-OH)+H]^+$	203.1390	203.1395	-0.093
				175.0868		
		$C_6H_{14}NO_2$	$[(H-MeVal-OH)+H]^+$	132.1014	132.1024	-3.824
		$C_4H_6NO_2$	$[Thr+H]^+$	100.0401	100.0398	7.947

Table S2. Gene organization of the actinomycins biosynthetic gene cluster in *Streptomyces* sp. MBT27 and similarities to corresponding protein sequences encoded by orthologues in the *S. antibioticus* IMRU 3720 biosynthetic gene cluster.

<i>S. antibioticus</i> IMRU 3720 gene	Function	<i>Streptomyces</i> sp. MBT27 actinomycin cluster ORF	Identity	Similarity
<i>saacmT</i>	Hypothetical protein	ORF01	0.80	0.89
<i>saacmS</i>	Hypothetical protein	ORF02	0.84	0.93
<i>saacmR</i>	MbtH-like protein	ORF03	0.86	0.94
<i>saacmD</i>	4-MHA carrier protein AcmAcp	ORF04	0.60	0.69
<i>saacmA</i>	Peptide synthetase ACMS I	ORF05	0.71	0.78
<i>saacmB</i>	Peptide synthetase ACMS II	ORF06	0.70	0.78
<i>saacmC</i>	Peptide synthetase ACMS III	ORF07	0.77	0.85
<i>saacmE</i>	Hypothetical protein	ORF08	0.91	0.93
<i>saacmF</i>	Aryl formamidase	ORF09	0.79	0.82
<i>saacmG</i>	Tryptophan 2,3-dioxygenase	ORF10	0.83	0.89
<i>saacmK</i>	Kynureninase	ORF11	0.86	0.91
<i>saacmL</i>	Methyltransferase	ORF12	0.88	0.93
<i>saacmM</i>	Cytochrome P450	ORF13	0.85	0.88
<i>saacmN</i>	Ferredoxin	ORF14	0.69	0.78
<i>saacmO</i>	LmbU-like protein	ORF15	0.72	0.80
<i>saacmP</i>	TetR family transcriptional regulator	ORF16	0.77	0.86
<i>saacmQ</i>	Siderophore-interacting protein	ORF17	0.76	0.85
<i>saacmR</i> A	ABC transporter ATPase subunit	ORF18	0.89	0.93
<i>saacmR</i> B	ABC 2-type transporter	ORF19	0.93	0.96
<i>saacmR</i> C	UvrA-like protein	ORF20	0.86	0.90

Table S3. X-ray crystallography data for 2.

	xs2313a
Crystal data	
Chemical formula	C ₆₉ H ₉₀ N ₁₄ O ₁₇ ·5.405(CH ₄ O)
<i>M</i> _r	1560.87
Crystal system, space group	Trigonal, <i>P</i> 3 ₂ 21
Temperature (K)	100
<i>a</i> , <i>c</i> (Å)	18.4731 (2), 42.4216 (5)
<i>V</i> (Å ³)	12537.1 (3)
<i>Z</i>	6
Radiation type	Cu <i>K</i> α
μ (mm ⁻¹)	0.77
Crystal size (mm)	0.23 × 0.15 × 0.07
Data collection	
Diffractometer	SuperNova, Dual, Cu at zero, Atlas
Absorption correction	Analytical <i>CrysAlis PRO</i> 1.171.40.53 (Rigaku Oxford Diffraction, 2019) Analytical numeric absorption correction using a multifaceted crystal model based on expressions derived by (Clark & Reid, 1995). Empirical absorption correction using spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm.
<i>T</i> _{min} , <i>T</i> _{max}	0.897, 0.957
No. of measured, independent and observed [<i>I</i> > 2σ(<i>I</i>)] reflections	90598, 14994, 13477
<i>R</i> _{int}	0.043
(sin θ/λ) _{max} (Å ⁻¹)	0.598
Refinement	
<i>R</i> [<i>F</i> ² > 2σ (<i>F</i> ²)], <i>wR</i> (<i>F</i> ²), <i>S</i>	0.046, 0.128, 1.03
No. of reflections	14994
No. of parameters	1091
No. of restraints	79




Figure S1. Chemical structure of actinomycin. Actinomycins are composed of a chromophore group highlighted with the red square and two pentapeptide chains, where amino acid AA2 and AA3 differs depending on the actinomycin group.




Figure S2. Representative results of antimicrobial activity of *Streptomyces* sp. MBT27 extracts against *B. subtilis* 168. *Streptomyces* sp. MBT27 was fermented in minimal medium (MM) with different carbon sources, namely (percentages in w/v): 1% of both mannitol and glycerol, 1% mannitol, 2% mannitol, 1% glycerol, 2% glycerol, 1% glucose, 2% glucose, 1% fructose, 1% arabinose, or 1% *N*-acetylglucosamine (GlcNAc), and extracted with ethyl acetate. The red boxes indicate active extracts of *Streptomyces* sp. MBT27, while the green boxes represent extracts without antibacterial activity against *B. subtilis* 168. Ampicillin was used as a positive control. Note, that extracts of cultures fermented with different carbon sources showed different bioactivity profiles.




Figure S3. Permutation validation of OPLS-DA model.




Figure S4 HRMS spectrum of 1.





Figure S5. HRMS spectrum of 2.

Figure S6. ^1H NMR spectrum of 1 (850 MHz, in CDCl_3 with TMS).




Figure S7. ^1H - ^1H TOCSY spectrum of **1** (850 MHz, in CDCl_3 with TMS).




Figure S8. ^1H - ^1H COSY spectrum of **1** (850 MHz, in CDCl_3 with TMS).




Figure S9. HSQC spectrum of 1 (850 MHz, in CDCl_3 with TMS).




Figure S10. HMBC spectrum of 1 (850 MHz, in CDCl_3 with TMS).




Figure S11. NOESY spectrum of **1** (850 MHz, in CDCl_3 with TMS).




Figure S12. Stacked ^1H NMR spectra of **1** and **2** (850 MHz, in CDCl_3 with TMS).




Figure S13. *S. antibioticus* is incapable to produces actinomycin L unless anthranilamide is supplied. Box plots showing the relative intensities of anthranilamide, actinomycin L₁ and L₂ after log transformation and pareto scaling in the cultures of *S. antibioticus* fermented for seven days in MM with different carbon sources 1. 1% fructose; 2. 1% fructose + 0.7 mM anthranilamide; 3. 1% glycerol; 4. 1% mannitol + 1% glycerol; 5. 2% glycerol (all %ages in w/v).




Figure S14. QTOF MS/MS spectrum of 4-MHB-containing pentapeptide lactone PPL 0.




Figure S15. QTOF MS/MS spectrum of 4-MHB-containing pentapeptide lactone PPL 1.




Figure S16. QTOF MS/MS spectrum of 4-MHB-containing pentapeptide lactone PPL 2.





Figure S17. QTOF MS/MS spectrum of 4-MHB-containing pentapeptide lactone PPL 3.

Figure S18. Alignment of actinomycin biosynthetic gene cluster from *S. antibioticus* and *Streptomyces* sp. MBT27. Grey arrows indicate genes with unknown function. Grey bars connecting homologues pairs from the two cluster, the identity of two genes is indicated by different levels of greyness.